Indoco Remedies USFDA ANDA approvals 2024: key generics

Why Indoco’s USFDA updates matter

Indoco Remedies has reported a series of US Food and Drug Administration (USFDA) decisions covering both tentative and final approvals under the Abbreviated New Drug Application (ANDA) pathway. These approvals and filings span large therapy areas such as type 2 diabetes, epilepsy, neuropathic pain, and opioid discontinuation treatment. For an Indian pharma exporter, such clearances directly influence the ability to launch products in the US regulated market. They also signal progress in building a steady pipeline of filings and approvals, especially when manufacturing sites are clearly identified.

The updates were disclosed through regulatory filings and subsequent media reports. In one instance, Indoco’s stock moved sharply on the back of an approval announcement. The company has also referenced USFDA inspections at its facilities, including timelines and outcomes where stated.

Tentative approval for canagliflozin plus metformin (diabetes)

Indoco Remedies said it received tentative approval from the USFDA for its ANDA for Canagliflozin and Metformin Hydrochloride tablets in various strengths. The tablets are positioned as a generic equivalent of Invokamet tablets. The strengths mentioned include 50 mg/500 mg, 50 mg/1000 mg, 150 mg/500 mg, and 150 mg/1000 mg. The company stated the product is used to treat type 2 diabetes mellitus.

The disclosure clarifies that the approval is tentative, which typically means the ANDA has met key requirements but cannot be finally approved until certain conditions are satisfied. Indoco indicated it plans to manufacture the product at its facility in Goa, India. The company also noted this step as an initial milestone before meeting remaining requirements for a final approval. No launch date or commercial terms were provided in the shared information.

Final USFDA approval for Brivaracetam Oral Solution

Indoco Remedies announced final approval from the USFDA for its ANDA for Brivaracetam Oral Solution, 10 mg/mL. The company said this allows it to market a generic equivalent to the reference listed drug (RLD), Briviact 10 mg/mL, of UCB, Inc. Indoco stated the oral solution has been determined to be bioequivalent and therapeutically equivalent to the RLD.

The company also disclosed that the product will be manufactured at its facility located at L-14, Verna Industrial Area, Verna, Goa - 403722, India. Media reports linked the approval to a positive stock reaction, noting Indoco Remedies shares climbed almost 7% after the announcement. The company described the approval as a milestone that strengthens its presence in regulated markets. Beyond the approval and manufacturing site, no further commercial rollout details were included.

Lofexidine tablets approval with 180 days exclusivity

Indoco Remedies also said it received final approval from the USFDA to market generic Lofexidine tablets, used in opioid discontinuation treatment. The approval was described as being accompanied by 180 days of competitive generic therapy exclusivity. The product covered in the update is Lofexidine tablets 0.18 mg.

Indoco said the approved product is a generic equivalent of Lucemyra tablets, 0.18 mg of USWM, LLC. The note ties the product to a specific therapeutic use case, but does not quantify market size or expected revenues. Exclusivity, where applicable, can shape early competition dynamics, but the only confirmed fact here is that the exclusivity period was stated as 180 days. The disclosure did not include a launch timeline.

Pregabalin capsules: multiple strengths cleared

Indoco Remedies said the USFDA granted final approval in May 2024 for its ANDA for Pregabalin capsules across several strengths: 25, 50, 75, 100, 150, 200, 225, and 300 mg. Indoco described the product as a generic version of Upjohn US 2 LLC’s reference listed drug, Lyrica capsules, across corresponding strengths. The company stated the capsules will be manufactured at its plant at L-14, Verna Industrial Area, Verna, Goa - 403722.

The article text also explains the medical uses of pregabalin, including neuropathic pain linked with diabetic peripheral neuropathy and spinal cord injury, postherpetic neuralgia, and fibromyalgia. Indoco repeated that manufacturing for this product will be done at its Goa facility. The information provided does not include pricing, supply agreements, or expected volumes. Still, it adds another product category to Indoco’s US portfolio beyond diabetes and CNS oral solutions.

Manufacturing footprint highlighted in filings

Across multiple products, Indoco repeatedly points to manufacturing at its Goa facility, including the Verna Industrial Area address. For Brivaracetam Oral Solution and Pregabalin capsules, the manufacturing location was explicitly cited. For Canagliflozin and Metformin Hydrochloride tablets as well, Indoco stated it plans to produce the medication at its manufacturing facility in Goa.

This level of site disclosure matters because ANDA approvals are tied to facility compliance and inspection status. When the same plant is referenced for several products, regulatory outcomes at that site can influence a broader set of launches. The article text does not mention capacity expansions or capex, so conclusions are limited to the locations and approvals stated.

USFDA inspections and compliance references

The text includes an FDA inspection timeline for an Indoco manufacturing facility in Goa, stating that the USFDA inspected the drug manufacturing facility at L 32 33 - 34 I D C Verna Industrial Road, Vasco Da Gama, Goa, India, from July 16 to 26, 2024. The excerpt also includes an instruction line to send an electronic reply to an FDA email address, indicating formal follow-up communication.

Separately, Indoco said in an exchange filing dated May 16 that the USFDA concluded an inspection at the company’s API Kilo Lab manufacturing facility in Navi Mumbai and the Indoco Analytical Solutions division. The company stated the inspection concluded with zero observations. The text does not specify whether the May 16 filing refers to 2024, but it is presented alongside other 2024 regulatory updates.

Market impact: stock reaction and investor focus

The most direct market reaction cited is that Indoco Remedies shares climbed almost 7% after the company received the final ANDA approval for Brivaracetam Oral Solution, as reported by CNBC TV 18. Such moves often reflect investor attention to the pace of approvals and potential US launch optionality. However, the available information does not provide revenue guidance, margin impact, or expected timelines.

For investors tracking Indian pharma exporters, the updates collectively show progress across several therapeutic segments and dosage forms. They also show a mix of tentative and final approvals, which can affect how quickly products reach the market. With multiple mentions of Goa-based manufacturing, investors may also pay attention to inspection outcomes and ongoing compliance at the listed facilities.

Key approvals and details (as reported)

What to watch next

Based on the information shared, the next practical step in the diabetes filing is conversion from tentative to final approval after remaining requirements are met. For products with final approvals, the key unknowns in the provided text are launch timing and commercial scale, which were not disclosed. On the compliance side, the inspection timelines and stated outcomes will remain relevant because multiple products cite Goa manufacturing.

Indoco’s updates show steady regulatory activity, with approvals spanning different therapy areas and product formats. The company has not provided financial impact figures in the text shared, but the approvals add to the set of products eligible for the US market. Further exchange filings, especially around final approvals and launches, will likely be the next confirmed checkpoints.